Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT)vsVertex Pharmaceuticals Inc (VRTX)
LABT
Lakewood-Amedex Biotherapeutics Inc. Common Stock
$1.83
+2.53%
HEALTHCARE · Cap: $4.86M
VRTX
Vertex Pharmaceuticals Inc
$522.38
+1.17%
HEALTHCARE · Cap: $130.87B
Smart Verdict
WallStSmart Research — data-driven comparison
VRTX leads profitability with a 35.0% profit margin vs 0.0%. VRTX earns a higher WallStSmart Score of 64/100 (C+).
LABT
Avoid23
out of 100
Grade: F
VRTX
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LABT.
Margin of Safety
+45.6%
Fair Value
$960.21
Current Price
$522.38
$437.83 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : LABT
The strongest argument for LABT centers on Price/Book, Debt/Equity.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Debt/Equity. Profitability is solid with margins at 35.0% and operating margin at 38.1%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : LABT
The primary concerns for LABT are Revenue Growth, EPS Growth, Market Cap.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
LABT profiles as a value stock while VRTX is a mature play — different risk/reward profiles.
VRTX is growing revenue faster at 12.5% — sustainability is the question.
VRTX generates stronger free cash flow (1.0B), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
VRTX scores higher overall (64/100 vs 23/100), backed by strong 35.0% margins and 12.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Lakewood-Amedex Biotherapeutics Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Labtec Inc. (Ticker: LABT) is a forward-thinking biotechnology company dedicated to revolutionizing drug delivery systems and diagnostic solutions. By leveraging cutting-edge technologies and fostering strategic partnerships, Labtec aims to address critical healthcare challenges and improve patient outcomes. With a comprehensive product portfolio and a strong commitment to meeting unmet medical needs, Labtec is well-positioned for substantial growth in the rapidly evolving biotech sector, representing a compelling investment opportunity for institutional investors.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?